| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.95 [0.85, 1.05] | | < 1 | | 0% | 3 studies (3/-) | 83.8 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.78 [0.66, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | important | - |
| DOR | 0.27 [0.16, 0.44] | | < 1 | | 35% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 0.59 [0.23, 1.49] | | > 1 | | 96% | 3 studies (3/-) | 13.2 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.14 [0.05, 0.40] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.21 [0.07, 0.65] | | < 1 | | 95% | 2 studies (2/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-5) | 1.53 [1.01, 2.33] | | < 1 | | 0% | 1 study (1/-) | 2.3 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 2.36 [1.02, 5.43] | | < 1 | | 67% | 2 studies (2/-) | 2.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.56 [0.12, 2.66] | | < 1 | | 98% | 3 studies (3/-) | 76.5 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 0.89 [0.69, 1.14] | | < 1 | | 29% | 2 studies (2/-) | 82.7 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.62 [0.31, 1.24] | | < 1 | | 89% | 3 studies (3/-) | 91.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.10 [0.05, 0.19] | | < 1 | | 75% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.18 [0.02, 1.31] | | < 1 | | 99% | 3 studies (3/-) | 95.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.01 [0.35, 2.96] | | < 1 | | 0% | 3 studies (3/-) | 48.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.46 [0.26, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.41 [0.11, 18.39] | | < 1 | | 0% | 2 studies (2/-) | 39.7 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.15 [0.02, 1.38] | | < 1 | | 95% | 3 studies (3/-) | 95.2 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Arthritis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.66 [0.33, 1.33] | | < 1 | | 4% | 3 studies (3/-) | 87.6 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.59 [0.20, 12.37] | | < 1 | | 0% | 2 studies (2/-) | 32.9 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.40 [0.04, 4.61] | | < 1 | | 0% | 2 studies (2/-) | 76.5 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.73 [0.24, 2.22] | | < 1 | | 0% | 3 studies (3/-) | 70.9 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.41 [0.11, 18.39] | | < 1 | | 0% | 2 studies (2/-) | 39.7 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.80 [0.22, 2.93] | | < 1 | | 42% | 2 studies (2/-) | 62.9 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 3.64 [0.16, 81.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.54 [0.18, 1.62] | | < 1 | | 36% | 3 studies (3/-) | 86.5 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.15 [0.01, 3.01] | | < 1 | | 0% | 1 study (1/-) | 89.0 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.50 [0.37, 33.12] | | < 1 | | 0% | 2 studies (2/-) | 13.9 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.45 [0.02, 13.55] | | < 1 | | 0% | 1 study (1/-) | 67.4 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.41 [0.11, 18.39] | | < 1 | | 0% | 2 studies (2/-) | 39.7 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.97 [0.27, 32.10] | | < 1 | | 0% | 2 studies (2/-) | 18.7 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.24 [0.20, 25.51] | | < 1 | | 0% | 2 studies (2/-) | 26.0 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.91 [0.13, 6.48] | | < 1 | | 0% | 1 study (1/-) | 53.9 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.74 [0.28, 26.45] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 6.46 [0.79, 52.82] | | < 1 | | 0% | 1 study (1/-) | 4.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.22 [0.01, 3.62] | | < 1 | | 75% | 2 studies (2/-) | 85.3 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 2.75 [0.28, 27.20] | | < 1 | | 0% | 2 studies (2/-) | 19.5 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 1.39 [0.11, 18.19] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.37 [0.07, 1.86] | | < 1 | | 41% | 3 studies (3/-) | 88.6 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 2.75 [0.28, 27.20] | | < 1 | | 0% | 2 studies (2/-) | 19.5 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.07 [0.00, 2.30] | | < 1 | | 89% | 3 studies (3/-) | 93.0 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 2.24 [0.20, 25.51] | | < 1 | | 0% | 2 studies (2/-) | 26.0 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.11 [0.01, 2.13] | | < 1 | | 0% | 1 study (1/-) | 92.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.18 [0.51, 19.85] | | < 1 | | 0% | 2 studies (2/-) | 10.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.65 [0.38, 18.62] | | < 1 | | 0% | 3 studies (3/-) | 16.5 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.23 [0.01, 5.02] | | < 1 | | 0% | 1 study (1/-) | 82.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 3.98 [0.84, 18.82] | | < 1 | | 0% | 3 studies (3/-) | 4.1 % | some concern | not evaluable | moderate | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.98 [0.02, 49.53] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.91 [0.06, 14.56] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 3.99 [0.84, 18.92] | | < 1 | | 0% | 1 study (1/-) | 4.1 % | NA | not evaluable | | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 1.82 [0.06, 54.35] | | < 1 | | 0% | 1 study (1/-) | 36.7 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.91 [0.02, 45.86] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.14 [0.01, 1.49] | | < 1 | | 83% | 3 studies (3/-) | 94.7 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.94 [0.06, 15.11] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.46 [0.04, 4.83] | | < 1 | | 61% | 2 studies (2/-) | 73.8 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 0.08 [0.05, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.51 [0.24, 1.10] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.22 [0.09, 0.54] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.54 [0.18, 1.61] | | < 1 | | 0% | 1 study (1/-) | 86.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.02 [0.00, 0.25] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.08 [0.01, 0.58] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.00 [0.00, 0.05] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.01 [0.00, 0.10] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.10 [0.01, 0.76] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
